RUNX2 and breast cancer: Even though inhibition of RUNX1-DNA binding by CADD522 was weaker than RUNX2-DNA binding in D-ELISA, we do not exclude the possibility that the in vitro and in vivo efficacy of CADD522 in BC models could also involve inhibition of RUNX1-DNA binding.